Savolitinib - AstraZeneca/HUTCHMED
Alternative Names: AZD-6094; HMP-504; HMPL-504; Orpathys; Volitinib; VoressaLatest Information Update: 10 Jun 2025
At a glance
- Originator Hutchison MediPharma
- Developer AstraZeneca; Hutchison MediPharma; HUTCHMED; National Cancer Institute (USA); Samsung Medical Center
- Class Antineoplastics; Imidazoles; Pyrazines; Pyrazoles; Pyridines; Small molecules; Triazoles
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase III Renal cell carcinoma
- Phase II Colorectal cancer; Gastric cancer; Oesophageal cancer; Prostate cancer
- No development reported CNS cancer; Solid tumours
Most Recent Events
- 02 Jun 2025 Efficacy and adverse event data from a phase III SACHI trial in Non-small cell lung cancer released by HUTCHMED
- 22 Apr 2025 Hutchison Medipharma completes enrolment in phase II trial in Gastric Cancer and Oesophageal cancer (Late-stage disease, Metastatic disease) (PO) (NCT04923932)
- 20 Mar 2025 Efficacy and adverse events data from a phase II SAVANNAH trial in Non-small cell lung cancer released by HUTCHMED